| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | ELL3 |
| Uniprot No | Q9HB65 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-397aa |
| 氨基酸序列 | MEELQEPLRGQLRLCFTQAARTSLLLLRLNDAALRALQECQRQQVRPVIAFQGHRGYLRLPGPGWSCLFSFIVSQCCQEGAGGSLDLVCQRFLRSGPNSLHCLGSLRERLIIWAAMDSIPAPSSVQGHNLTEDARHPESWQNTGGYSEGDAVSQPQMALEEVSVSDPLASNQGQSLPGSSREHMAQWEVRSQTHVPNREPVQALPSSASRKRLDKKRSVPVATVELEEKRFRTLPLVPSPLQGLTNQDLQEGEDWEQEDEDMGPRLEHSSSVQEDSESPSPEDIPDYLLQYRAIHSAEQQHAYEQDFETDYAEYRILHARVGTASQRFIELGAEIKRVRRGTPEYKVLEDKIIQEYKKFRKQYPSYREEKRRCEYLHQKLSHIKGLILEFEEKNRGS |
| 分子量 | 69.41 kDa |
| 蛋白标签 | GST-tag at N-terminal |
| 缓冲液 | 0 |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于重组人ELL3蛋白的假设性参考文献示例，基于相关领域的研究方向整理。请注意，部分文献可能是综合现有知识的合理推测，实际引用时请以具体文献为准：
---
1. **文献名称**：*"Recombinant Human ELL3 Enhances Transcriptional Elongation by RNA Polymerase II in Stem Cells"*
**作者**：Chen, L., et al.
**摘要**：本研究报道了在大肠杆菌系统中成功表达并纯化重组人ELL3蛋白，验证其与RNA聚合酶II的相互作用，证实其通过促进转录延伸调控胚胎干细胞多能性基因(如OCT4、NANOG)的表达。
2. **文献名称**：*"Structural Insights into ELL3’s Role in Leukemogenesis"*
**作者**：Wang, Y., et al.
**摘要**：通过晶体学解析重组hELL3的N端结构域，揭示其与致癌转录因子(如RUNX1)的结合模式，并发现其在急性髓系白血病细胞中异常高表达，促进细胞增殖和凋亡抵抗。
3. **文献名称**：*"ELL3 Modulates Androgen Receptor Signaling in Prostate Cancer via Recombinant Protein Interaction Assays"*
**作者**：Kim, S., et al.
**摘要**：利用重组ELL3蛋白进行体外互作实验，证明其通过调控雄激素受体(AR)的转录延伸活性促进前列腺癌细胞生长，提示其作为潜在治疗靶点。
4. **文献名称**：*"Development of a High-Yield Expression System for Recombinant ELL3 and Functional Screening in DNA Damage Response"*
**作者**：Garcia, R., et al.
**摘要**：优化昆虫细胞系统中的hELL3重组表达工艺，发现其参与DNA损伤修复通路的转录调控，影响ATM/ATR信号通路的基因表达。
---
**备注**：上述文献为示例性质，若需真实文献，建议在PubMed或Google Scholar中搜索关键词“Recombinant human ELL3”、“ELL3 transcription elongation”或结合具体研究领域筛选。
Recombinant human ELL3 (Eleven-Nineteen Lysine-rich Leukemia protein 3) is a member of the ELL family of RNA polymerase II (RNA Pol II)-interacting transcription elongation factors. Initially identified through its homology to ELL1. a gene implicated in acute myeloid leukemia via chromosomal translocations, ELL3 shares conserved structural domains, including an N-terminal elongation domain critical for its function. Unlike ELL1 and ELL2. which are ubiquitously expressed, ELL3 exhibits tissue-specific expression, predominantly in germ cells, stem cells, and certain cancers, suggesting specialized roles in development and oncogenesis.
Recombinant ELL3 is engineered using heterologous expression systems (e.g., E. coli, mammalian cells) to study its biochemical properties and cellular functions. Purified recombinant ELL3 enables exploration of its interactions with RNA Pol II, chromatin modifiers, and non-coding RNAs. Studies reveal its dual role in transcription regulation: promoting elongation by suppressing transient pausing of RNA Pol II and participating in epigenetic modulation through histone modification complexes.
ELL3's involvement in pluripotency maintenance, germ cell differentiation, and cancer progression (e.g., prostate, ovarian cancers) highlights its biomedical relevance. Paradoxically, it may act as an oncogene or tumor suppressor depending on cellular context, underscoring its complex regulatory networks. Current research focuses on its molecular mechanisms in development, stress responses, and therapeutic targeting. The availability of recombinant ELL3 facilitates structural studies, inhibitor screening, and functional assays to unravel its pathophysiological roles.
×
